All Stories

  1. Morphology-dependent toxicity and MRI contrasting properties of Mn3O4 nanostructures: A comparative study
  2. Diosmetin attenuates chronic unpredictable mild stress induced-depression-like behavior in mice via modulation of oxidative stress, neuroinflammation, and the gut–brain axis
  3. Targeting TLR4/NF-κB/NLRP3 signaling with 6-hydroxyflavanone mitigates amyloid-β-induced Alzheimer’s disease in mice
  4. Quantitative Structure–Activity Relationship Approaches for Exploring the Anticancer Potential of Flavonoids
  5. Malvidin and its glycosides in cancer treatment: Mechanisms, synergies and drug delivery strategies
  6. Dietary Isoflavone Biochanin A Attenuates Aluminium Chloride-Induced Sporadic Alzheimer’s Disease and Associated Neurobehavioral Alterations Through NRF2-HO1 Pathway Activation and NLRP3 Inflammasome Suppression
  7. Understanding Different Signaling Involved During Oxidative Stress
  8. Quercetin as therapeutic modality for inflammatory diseases: Where we are and where to go?
  9. Protective Effect of Fisetin on Subacute and Chronic Arsenic and Fluoride Co‐Exposure Induced Hepatic, Renal and Cardiac Toxicities in Mice
  10. Role of microbiota-gut-brain axis in epilepsy and possible interventions
  11. Impact of Oxidative Stress and Neuroinflammation on Sarco/Endoplasmic Reticulum Ca2+-ATPase 2b Downregulation and Endoplasmic Reticulum Stress in Temporal Lobe Epilepsy
  12. Nanoformulated fisetin ameliorates Alzheimer's disease via reducing proinflammatory cytokines and activating the NRF2/HO-1 pathway
  13. Harnessing Therapeutic Potentials of Biochanin A in Neurological Disorders: Pharmacokinetic and Pharmacodynamic Overview
  14. Fisetin-loaded chitosan nanoparticles ameliorate pilocarpine-induced temporal lobe epilepsy and associated neurobehavioral alterations in mice: Role of ROS/TNF-α-NLRP3 inflammasomes pathway
  15. Introduction to Complex Brain Disorders, Currently Available Therapies, and Their Limitations
  16. Toxicity Issues of Nanoparticles in the Delivery of Phytoconstituents and Cosmeceuticals
  17. Insights into role of microRNA in Alzheimer's disease: From contemporary research to bedside perspective
  18. Functional Implications of Protein Arginine Methyltransferases (PRMTs) in Neurodegenerative Diseases
  19. Flavonoids as promising anticancer therapeutics: Contemporary research, nanoantioxidant potential, and future scope
  20. Vitamin E modified polyamidoamine dendrimer for piperine delivery to alleviate Aβ 1–42 induced neurotoxicity in Balb/c mice model
  21. Fisetin attenuates arsenic and fluoride subacute co-exposure induced neurotoxicity via regulating TNF-α mediated activation of NLRP3 inflammasome
  22. Effect of organic solvents on acetylcholinesterase inhibition and enzyme kinetics
  23. The Pharmacological Activity of Garlic (Allium sativum) in Parkinson’s Disease: From Molecular Mechanisms to the Therapeutic Potential
  24. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
  25. Hybrid Quantum Dot as Promising Tools for Theranostic Application in Cancer
  26. Bioactive Flavonoids: A comparative overview of the biogenetic and chemical synthesis approach
  27. Optimisation of tacrolimus dose in fast metabolisers by genotyping
  28. Herbal Approaches for the Management of Neurological Disorders
  29. Pathophysiology and Management Approaches for Huntington’s Disease, Multiple Sclerosis, and Other Neurological Disorder
  30. Pathophysiology and Management Approaches for Traumatic Brain Injury
  31. Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope
  32. Utilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone
  33. Capillary Electrophoresis
  34. Enzyme-Linked Immunosorbent Assay
  35. Flavonoids and stilbenoids as a promising arsenal for the management of chronic arsenic toxicity
  36. CRISPR‐based point‐of‐care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS‐CoV‐2 detection
  37. DNA Methylation: A Promising Approach in Management of Alzheimer’s Disease and Other Neurodegenerative Disorders
  38. Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
  39. Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
  40. Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements
  41. Protective Effect of Monoisoamyl-2, 3-Dimercaptosuccinic Acid against Manganese-induced Neurotoxicity in Rats
  42. PTZ kindling model for epileptogenesis, refractory epilepsy, and associated comorbidities: relevance and reliability
  43. Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
  44. Effect of Early Lockdown in India During the Outbreak of COVID-19: A Comparative Study of USA, Italy and India
  45. Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities
  46. In silico screening of pyridoxine carbamates for Anti-Alzheimer’s activities
  47. Polymer-Lipid Hybrid Systems: Scope of Intravenous-To-Oral Switch in Cancer Chemotherapy
  48. Effect of hesperidin on fluoride‐induced neurobehavioral and biochemical changes in rats
  49. Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
  50. Curcumin loaded nanoparticles reversed monocrotophos induced motor impairment and memory deficit: Role of oxidative stress and intracellular calcium level
  51. Modulatory Effect of Serotonergic System in Pentylenetetrazole-Induced Seizures and Associated Memory Deficit: Role of 5-HT<sub>1A</sub> and 5-HT<sub>2A/2C</sub>
  52. Role of curcumin and its nanoformulations in neurotherapeutics: A comprehensive review
  53. Rational approaches for toxicological assessments of nanobiomaterials
  54. Oxidative stress and neurobehavioural changes in rats following copper exposure and their response to MiADMSA and d-penicillamine
  55. Impact of chronic low dose exposure of monocrotophos in rat brain: Oxidative/ nitrosative stress, neuronal changes and cholinesterase activity
  56. Relative Safety of Different Antidepressants for Treatment of Depression in Chronic Epileptic Animals Associated with Depression
  57. Chronic 5-HT3 receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice
  58. Anticonvulsant mechanisms of piperine, a piperidine alkaloid
  59. Revealing Medicinal Plants That Are Useful for the Comprehensive Management of Epilepsy and Associated Comorbidities through In Silico Mining of Their Phytochemical Diversity
  60. Comparative behavioral and neurochemical analysis of phenytoin and valproate treatment on epilepsy induced learning and memory deficit: Search for add on therapy
  61. Adjuvant Anticholinesterase Therapy for the Management of Epilepsy‐Induced Memory Deficit: A Critical Pre‐clinical Study
  62. Psychoneurochemical Investigations to Reveal Neurobiology of Memory Deficit in Epilepsy
  63. Effect of saponin fraction from Ficus religiosa on memory deficit, and behavioral and biochemical impairments in pentylenetetrazol kindled mice
  64. Ameliorative effect of Curcumin on seizure severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice
  65. Naturally occurring himachalenes to benzocycloheptene amino vinyl bromide derivatives: as antidepressant molecules
  66. Age dependent learning and memory deficit in Pentylenetetrazol kindled mice
  67. Anticonvulsant activity of Passiflora incarnata: No role of chrysin
  68. Ameliorative Effect of the Cinnamon Oil fromCinnamomum zeylanicumupon Early Stage Diabetic Nephropathy